Montes Worboys, AnaMilara, JavierFarrera, ConsolFernández Asensio, CristinaSánchez Díez, SilviaMercadé, JaumeMontero, PaulaRoger Laparra, InésMolina Molina, MaríaRuiz Cánovas, Eugèniaet al.2026-02-042026-02-042026Montes-Worboys, A., Milara, J., Farrera, C., Fernández-Asensio, C., Sánchez-Díez, S., Mercadé, J., Montero, P., Roger, I., Molina-Molina, M., Ruiz-Cánovas, E., & Cortijo, J. (2026). GTX-11 attenuates lung fibrosis, inflammation and vascular remodeling in preclinical models of lung fibrotic disease. Frontiers in Pharmacology, 16, 1671132. https://doi.org/10.3389/fphar.2025.16711321663-9812https://hdl.handle.net/11268/16791Fibrotic interstitial lung diseases (ILDs) are characterized by different degrees of inflammation and fibrosis of the lung parenchyma that are associated with progressive loss of breath, high morbidity and mortality. Current therapeutic options are limited, so there remains a significant need for effective and well-tolerated treatments. GTX-11 is an orally available small molecule in development for the treatment of fibrotic diseases. In this study, we aimed to assess the therapeutic potential of GTX-11 in different preclinical models of lung fibrotic disease. Altogether, our studies reveal that GTX-11 is an effective antifibrotic both in vivo and in vitro, suggesting that GTX-11 has potential as a therapeutic option for fibrotic ILDs.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal article10.3389/fphar.2025.1671132open accessCiencias médicasFarmacologíaAparato respiratorioGoal 3: Ensure healthy lives and promote well-being for all at all ages